Skip to main content

Vivos Therapeutics, Inc.

VVOS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001716166

No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Vivos Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of VVOS: Q1 2025 compared with Q2 2025
MeasureQ1 2025Of which not filed for Q2 2025Q2 2025Change
Holders21119−1
Shares351.2K2.37K402.1K+53.3K (+15.3%)
Value$1.00M$6.74K$1.27M+$277.3K (+27.9%)

1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Vivos Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to VVOS in Q2 2025
InstitutionSharesValue% of portfolio
XTX Topco Ltd20,528$64.9K0.00%
Tower Research Capital LLC (TRC)497$1.57K0.00%
Raymond James Financial Inc74$2340.00%
Global Retirement Partners, LLC23$730.00%

Sold out (5)

Institutions that held Vivos Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of VVOS in Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
Cutter & CO Brokerage, Inc.49,100$139.9K
Envestnet Asset Management Inc38,873$110.8K
Ewa, LLC10,464$29.8K
Group One Trading, L.P.228$650
Barclays PLC1$3

Not filed for Q2 2025 yet (1)

Institutions that held Vivos Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VVOS in Q1 2025 that haven't filed for Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
Credit Agricole S A2,365$6.74K